Acadia Pharmaceuticals Holds Annual Meeting, Elects Directors

On Thursday, Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company with a market capitalization of $3.73 billion and an impressive 50% stock return over the past year, announced the results of its 2025 Annual Meeting of Stockholders, which was held on May 29, 2025. According to InvestingPro analysis, the company maintains excellent financial health with strong profitability metrics. The company reported on the election of its Class III directors and other key matters, including executive compensation and the appointment of its independent registered public accounting firm.

At the meeting, stockholders elected three Class III directors to serve on the company’s Board of Directors until the 2028 Annual Meeting. The elected directors are Catherine Owen Adams, Laura A. Brege, and Elizabeth A. Garofalo, M.D., with Adams receiving 142,149,434 votes for, Brege receiving 129,105,717 votes for, and Garofalo receiving 140,048,500 votes for. Votes withheld and broker non-votes were also reported for each candidate.

Additionally, stockholders approved, on an advisory basis, the compensation of the company’s named executive officers as disclosed in the definitive proxy statement filed on April 25, 2025. The compensation was approved with 142,156,754 votes for, 2,807,251 against, and 108,814 abstentions. There were also 10,343,307 broker non-votes on this matter.

Ernst & Young LLP was ratified as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The appointment received overwhelming support with 154,454,616 votes for, 926,490 against, and 35,019 abstentions.

These voting results are considered final. The information provided in this article is based on a press release statement. The company’s strong financial position is reflected in its healthy current ratio of 2.88 and positive net income of $228.88 million in the last twelve months. InvestingPro subscribers have access to 12 additional key insights about ACAD, including detailed valuation metrics and growth forecasts in the comprehensive Pro Research Report.

In other recent news, Acadia Pharmaceuticals has made several noteworthy developments. The company recently announced the appointment of Allyson McMillan-Youngblood as the new Senior Vice President of its Rare Disease Franchise, aiming to bolster growth in its DAYBUE® brand and prepare for future product launches. Deutsche Bank (ETR:DBKGn) upgraded Acadia’s stock from Hold to Buy, raising the price target to $35 due to a favorable patent litigation outcome for Nuplazid, which extends its patent protection until 2038. This legal victory also prompted BMO Capital Markets to increase its price target to $28, highlighting the significance of the extended intellectual property protection for the company’s financial outlook.

Additionally, Acadia has secured a new lease for office space in Princeton, New Jersey, which will serve as its executive and research and development hub. The company also amended its existing lease to ensure a smooth transition to the new premises. RBC Capital Markets continues to maintain an Outperform rating on Acadia, citing optimism over accelerated timelines for its Phase III ACP-101 program in Prader-Willi Syndrome. The anticipation of upcoming clinical data releases and Acadia’s first R&D Day in June 2025 is also contributing to positive sentiment among investors.

These developments underline Acadia’s strategic focus on growth and legal protection of its intellectual property, which are seen as critical factors for its long-term financial health. Analysts from Deutsche Bank and BMO Capital Markets have expressed increased confidence in Acadia’s future revenue streams and overall market position. The company remains poised for potential growth, with key updates expected in the coming months.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.